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Executive summary
A high-throughput multiplexed assay (Multiplex Version 1.0) was developed for the differential 
laboratory diagnosis of foot-and-mouth disease virus (FMDV) from viruses which cause 
clinically similar diseases of livestock.  This assay simultaneously screens for five RNA and two 
DNA viruses using multiplexed reverse transcription PCR (mRT-PCR) amplification coupled 
with a microsphere hybridization array and flow-cytometric detection.  Two of the seventeen 
primer-probe sets included in this multiplex assay were adopted from previously characterized 
real-time RT-PCR (rRT-PCR) assays for FMDV.  The diagnostic accuracy of the mRT-PCR was 
evaluated using 287 field samples, including 248 (true positive n= 213, true negative n=34) from 
suspect cases of foot-and-mouth disease collected from 65 countries between 1965 and 2006 and 
39 true negative samples collected from healthy animals.  The mRT-PCR assay results were 
compared with two singleplex rRT-PCR assays, using virus isolation with antigen-ELISA as the 
reference method.  The diagnostic sensitivity of the mRT-PCR assay for FMDV was 93.9% 
[95% C.I. 89.8-96.4%], compared to 98.1% [95% C.I. 95.3-99.3%] for the two singleplex rRT-
PCR assays used in combination. In addition, the assay could reliably differentiate between 
FMDV and other vesicular viruses such as swine vesicular disease virus and vesicular exanthema 
of swine virus.  Interestingly, the mRT-PCR detected parapoxvirus (n=2) and bovine viral 
diarrhea virus (n=2) in clinical samples, demonstrating the screening potential of this mRT-PCR
assay to identify viruses in FMDV-negative material not previously recognized using focused 
single-target rRT-PCR assays.
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1. Introduction
Foot-and-mouth disease (FMD) is a highly infectious and contagious vesicular disease 
affecting domestic and wild ruminants and swine caused by a single-stranded positive-sense 
RNA virus having seven distinct serotypes (A, Asia 1, C, O, SAT 1, SAT 2 and SAT 3) (17).  
FMD is endemic in many countries throughout the world, with serotype O having the highest 
prevalence, followed by serotype A (9). Early detection of the virus is critical to minimizing 
disease spread and the significant economic implications (12) resulting from the introduction of 
FMD into a country previously free of the disease.  Diagnosis of FMD can be confounded by 
diseases with similar clinical signs (“look-alike” diseases), and by species where presentation of 
the disease is mild or indistinct (16).  For the laboratory identification of FMDV, the Office 
International des Epizooties (OIE) recommends virus isolation (VI), antigen-ELISA (Ag-
ELISA), and RT-PCR with detection by agarose gel electrophoresis or in real-time using 
TaqMan® fluorogenic probes (15).  
Real-time PCR is widely used by diagnostic laboratories, to complement or as a replacement 
for more traditional detection methods.  Two independent real-time reverse transcription 
polymerase chain reaction (rRT-PCR) assays for FMD laboratory diagnosis target the ribosomal 
entry site of the 5´untranslated region (5´UTR) (30) and the viral RNA polymerase gene (3D) (4)
on the highly variable FMDV genome.  The 5´UTR and 3D rRT-PCR assays were initially 
compared prior to their implementation in Australia (3). A subsequent in-depth comparative 
evaluation (14) was conducted to further evaluate the effectiveness of these assays; 
demonstrating a higher diagnostic sensitivity of the rRT-PCR assays over VI and/or antigen-
ELISA (35), particularly when both assays were used in combination.  Both assays are used 
routinely in combination at the Food and Agriculture Organization of the United Nations, World 
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Reference Laboratory (FAO WRL) for FMD. rRT-PCR assays have also been reported for the 
detection of other viruses which cause vesicular disease of livestock including swine vesicular 
disease (SVD) (29), vesicular stomatitis (VS) (11, 28) and vesicular exanthema of swine (VES) 
(31) or symptomatic look-alike diseases including bluetongue (13, 27, 33), bovine viral diarrhea 
(1, 2, 20, 22, 39), malignant catarrhal fever (37) and parapoxvirus (26).  
Fluorescent probes for rRT-PCR detection have broad emission spectra which limit 
multiplexing capacity to the four or five discrete optical channels typically present in most 
commercial real-time PCR instruments.  Therefore, simultaneous testing for FMDV and look-
alike disease viruses by rRT-PCR would require many assays to be run in parallel, thereby 
increasing the demand on instrumentation and reagents which escalates costs.  A single 
multiplexed screening test that simultaneously detects and differentiates FMDV from look-alike 
disease viruses would be desirable.  Such a test could facilitate rapid and cost-effective screening 
of suspect FMD field samples for laboratory differential diagnosis, targeted FMD surveillance, 
or embedded foreign animal disease surveillance whilst conducting routine testing for endemic 
diseases.
Luminex xMAP technology is a multiplexed high-throughput detection system (38) with many 
applications for nucleic acid detection (6).  The Luminex array offers up to 100 independent 
channels using microspheres (5.6 mm) embedded with varying ratios of two fluorescent dyes.  
User-defined surface modifications can include oligonucleotides, antibodies, peptides or other 
macromolecules. Typically, a mixed suspension of functionalized microspheres is mixed with 
the sample to bind analytes which are then labeled with a fluorescent reporter and analyzed using 
a specialized flow-cytometer.  The assay provides end-point detection with qualitative results by 
comparing fluorescence responses (median fluorescence intensity, MFI) of each microsphere 
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class to cut-off values.  Recent nucleic acid applications of the Luminex array include the 
detection and differentiation of Classical swine fever virus from other pestiviruses (5), human 
respiratory viruses (18, 19, 21, 23), human papillomavirus (10, 32) and human influenza A virus 
typing (40).
This report describes a novel multiplexed RT-PCR microsphere array assay for the differential 
detection of FMDV from look-alike disease viruses. The development, optimization and 
analytical evaluation of this multiplex assay will be reported separately.  The primary purpose of 
this study was to evaluate the diagnostic performance of the mRT-PCR assay for the detection of 
FMDV using a panel of suspect field samples.  The diagnostic sensitivities of the 3D and 5´UTR 
FMDV assays in mRT-PCR format were compared to rRT-PCR using VI with Ag-ELISA as the 
reference method.  The detection of look-alike diseases in suspect FMD field samples is also 
reported.
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2. Materials and Methods
2.1. Samples
The panel comprised epithelia (true positive n= 213, true negative n=34) from suspect field
cases of FMD submitted from 65 countries to the FAO WRL for FMD between 1965 and 2006 
and included representatives of all seven serotypes of FMDV.  In addition, 39 samples of true 
negative tongue epithelial were collected from healthy cattle at a UK abattoir.  All sample testing 
and reference measurements were conducted at the FAO WRL for FMD.  Epithelia were ground 
and suspended to generate a ~10% w/v suspension in phosphate buffer (0.04M, pH 7.6).  The 
epithelial suspensions (ES) were centrifuged, the supernatant collected, then stored at -80ºC.  
FMDV serotype was determined by conducting an antigen-ELISA (8) on the original ES or after 
viral propagation in cell culture.  Samples of look-alike viruses from the FAO WRL for FMD 
collection included SVDV, VESV, San Miguel sea lion virus (SMSV), caliciviruses isolated 
from a variety of species (including cetacean, bovine, feline, reptile, skunk) and vesicular 
stomatitis virus (VSV).
2.2. Nucleic acid extraction
Total nucleic acid was extracted from each ES by an automated procedure using a MagNA 
Pure LC (Roche, UK) as previously described (14, 35). Extracted samples (40 mL) were 
aliquoted (3×13 mL), stored at -80ºC and thawed once just before use.
2.3. rRT-PCR
Previously reported protocols for the individual 3D (4) and 5´UTR (34) rRT-PCR assays were 
modified for use in this study. Briefly, 25 μl reaction mixes (SuperScriptTM III Platinum® One-
Step qRT-PCR System (Invitrogen)) containing 20 pmol of each primer, 7.5 pmol of dual-
labelled TaqMan® probe and 5 μl total nucleic acid were prepared in an optical reaction plate
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(Stratagene, Amsterdam, The Netherlands). For both targets, RT-PCR amplification was 
performed in an Mx4000 Multiplex Quantitative PCR System (Stratagene) as described 
previously (34).  
2.4. mRT-PCR assay design  
A schematic depiction of the mRT-PCR assay is shown in Figure 1.  The RT-PCR uses 
eighteen biotinylated forward and unmodified reverse primer sets (17 for detection, 1 serves as a 
control).  
Figure 1: Schematic of the multiplex RT-PCR assay.  In the presence of target nucleic 
acid, the biotinylated forward primer is extended during the PCR. The PCR product is 
hybridized to the microsphere array, whereby the extended forward primer binds to the 
complementary probe-labeled microsphere.  The complex is labeled with fluorescent 
reporter (SAPE) then analyzed using a Bio-Plex flow cytometer. The fluorescence (570 
nm) of bound reporter molecules is measured, and the median fluorescence intensity is 
calculated for each microsphere class, then compared to a cut-off to indicate the presence 
or absence of a target nucleic acid sequence in a sample.
The sequences that comprise the multiplex assay are shown Table 1. The multiplex assay was 
designed to detect and differentiate FMDV from SVDV, VESV, Bovine Viral Diarrhea Virus 
(BVDV), Bluetongue Virus (BTV), Parapox viruses (Orf virus, pseudocowpox virus, and bovine 
papular stomatitis virus), and Bovine Herpes Virus-1 (BHV-1).  Primer-probe sequences for 
FMDV (4, 30) and BVDV (7, 22) were based on the work of others and adapted to the current 
multiplex format.  All other sequences were designed at Lawrence Livermore National 
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Laboratory (LLNL) using an approach that has previously been described (36).  Additional 
computational analyses were performed to ensure specificity and reliability against all available 
data, including a BLAST-based comparison of each primer-probe set as a triplet against all 
sequences in GenBank to identify the targets that are predicted to produce a PCR or TaqMan 
reaction at 57 ºC for primer annealing and 67 ºC for probe annealing, where temperatures are 
derived from Primer 3 oligo TM calculations.  Optimal candidate primer-probe sets were 
forwarded to the bench screening phase for further down-selection.  Amplicon sizes ranged from 
95 -349 bp.
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Table 1: Primer and probe sequences of the multiplex RT-PCR assay.
Assay 
name
Forward Primer (5´à3´)
Reverse Primer (5´à3´)
Probe (5´à3´)
BHV 1 GŦGCCAGCCGCGŦAAAAG
GACGACTCCGGGCTCTTTT
TCCTGGTTCCAGAGCGCTAACATGGAG
BHV 2 TGAGGCCŦATGTATGGGCAGŦT
GCGCGCCAAACATAAGTAAA
AAATAACACGGTGTGCACTTAAATAAGATTCGCG
BTV 1 GCACCCŦATATGTTŦCCAGACCA
CAGCTAACTCTTCAGCCACACG
CTAACTCGTGGGCCAATCATCATCTTCTGT
BTV 2 AGAATŦCAGGAŦGGGCAGGA
GCACAATTCCCATCCCCTTA
CCATCACACCATTATACTGTACCCGCGTAGC
BVDV GGTAGTCGŦCAGTGGTŦCGAC
CATGTGCCATGTACAGCAGAGAT
CCTCGTCCACGTGGCATCTCGAG
FMDV 
3D
ACTGGGŦTTTACAAACCŦGTGA
GCGAGTCCTGCCACGGA
GTCCCACGGCGTGCAAAGGA
FMDV 
5´UTR
CACYTYAAGRŦGACAYTGRTACŦGGTAC
CAGATYCCRAGTGWCICITGTTA
CCTCGGGGTACCTGAAGGGCATCC
PPOX 1 GCAGAŦGCGCTCCŦGGTT
GCACCTCTGCTGCTGCAA
CCGACTCCGACGTGGAGAACGTG
PPOX 2 GATGGCCGŦGCAGCŦCTT
CGTACAAGATCACGGCCAACT
TGTACGGGCTCATGGGCTTCCG
PPOX 3 GCAGCAGŦGCACCACGŦAGT
CGCTGAACCCGTACATCCT
GACTTCGAGGCGGACAACAAGCG
SVDV 1 CAGGAŦAATTTCTŦCCAAGGGC
ACGTGAACATTTCGAGCTTCC
TGCATTGTGTCTGATGGTACAACTTGTGACG
SVDV 2 GACTTGŦTGTGGCŦGGAGGA
CAGCGCCATGGTGAGGTAG
TGACCGTAATGAGGTCATCGTGATTTCTCAC
SVDV 3 GACAAAGŦGGCCAAGGGAAA
CACGTAAACCACACTGGGCT
CTGGCGTCATAGCCTGAATAGTCAAACGCTA
VESV 1 GCCTŦCTCCCTŦCCCAAAA
TGAAGGAATGGTTCCGTCAGT
CATCATCGTTGATAACCTTAGATGTGCAATTTGG
VESV 2 GGGAAŦGAGGTGTGCAŦCATT
CACGTCTTGATGTTGGCTTGAC
AAATTGGCATAATCAACCTTGTCAGATGAGTCG
VESV 3 GGTCGCŦCTCACTGATGAŦGAGTA
GGTGTTATCAGCACCCATTGC
GCTCGGTGCCTGAGTTGGAGGAAG
VESV 4 ACCACCŦCTGGAAACATCŦATGG
TTTGTGCACGTGTCACGAAT
CGGGACGGGCATTTGTCACCA
FC N/A CAAAGŦGGGAGACGTCGŦTG
IC N/A CAAAGTGGGAGACGTCGTTG-Cy3
NC N/A CAAAGTGGGAGACGTCGTTG
BHV = bovine herpes virus-1, PPOX = parapox virus complex, FMDV = foot-and-mouth disease 
virus, BVDV = Bovine Viral Diarrhea Virus, BTV = bluetongue virus, SVDV = swine vesicular 
disease virus, VESV = vesicular exanthema of swine virus, NC = negative control, FC = 
fluorescence control, IC = instrument control, Cy3 = fluorescent cyanine dye, Y = pyrimidines 
(C/T), R = purines (A/G), W = weak 2-bonds (A/T), I = inosine (universal base). Ŧ = an internal 
biotinylated dT. All forward primers also include biotinylation at the 5´ terminus. All probes 
contain an amine attached to the 5´ terminus with a carbon 6 and internal spacer 18. N/A = not 
applicable.
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2.5. mRT-PCR primers and probes  
All oligonucleotides used for mRT-PCR were synthesized by Integrated DNA Technologies 
(IDT, Coralville, IA) and HPLC-purified.  Forward primers were functionalized with 5´ and 
internal biotin moieties.  Reverse primers were unmodified.  Probes were 5´ amino C6-modified 
with an 18-atom hexaethyleneglycol spacer.  Lyophilized probe was dissolved in 2-(N-
morphilino)ethanesulfonic acid (MES) to yield a stock concentration of 1 mM.  Lyophilized 
forward and reverse primers were dissolved in TE buffer to yield a stock concentration of 1 mM.  
Working dilutions were prepared from the stock solutions as required.  
2.6. Coupling of probe oligonucleotides to microspheres
xMAP® Multi-Analyte COOH Microspheres (Luminex Corp., Austin, TX) were covalently 
coupled to probe oligonucleotides using carbodiimide activation based on the manufacturer’s 
protocol.  Briefly, stock microspheres (1 mL, 1.25x107 microspheres) were vortexed for 30 s, 
sonicated for 60 s, centrifuged at 8000 ×g for 5 min and the supernatant removed.  The 
microspheres were then resuspended in MES (50 mL, 0.1M, pH 4.5), vortexed and sonicated.  
Probe (10 mL, 50 mM in MES) was added and the mixture vortexed.  An aqueous solution of N-
(3-dimethylaminopropyl)-N´-ethylcarbodiimide hydrochloride (EDC; 5 mL, 10 mg/mL) was 
added, vortexed, then gently agitated for 30 min in the dark.  A second aliquot of EDC (5 mL, 10 
mg/mL) was added, vortexed, then gently agitated for 30 min in the dark.  Tween 20 (1 mL, 
0.02% v/v) was added, vortexed, centrifuged, the supernatant removed, then repeated using SDS 
(1 mL, 0.1% m/v) then TE buffer (100 mL 1 mM Tris, 10 mM EDTA, pH 7.4).  The probe-
conjugated microspheres were resuspended in TE buffer (250 mL), vortexed, then stored at 4°C 
in the dark.  
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2.7. Microsphere mixture  
A 21-plex microsphere suspension was prepared by combining individual stock suspensions (9 
mL/class) with Tris-NaCl buffer (3 mL).  The mixture was vortexed then enumerated using the 
Bio-Plex, targeting approximately 150 microspheres counts per class in 40 s.  If required, 
additional microspheres from the individual stocks were added to ensure the concentrations of all 
classes were approximately equal.
2.8. mRT-PCR amplification.  
Each field sample was analyzed in duplicate by the multiplex assay.  Amplification was 
performed using a one-step RT-PCR kit (SuperScript™ III One-Step RT-PCR System with 
Platinum® Taq DNA Polymerase, Invitrogen).  The reaction volume of 25 mL was comprised of 
nuclease-free water (0.95 mL), primer mix (3.6 mL), SuperScript™ III 2X reaction mix (12.5 
mL), MgSO4 (0.95 mL, 50 mM, Invitrogen), SuperScript™ III RT / Platinum® Taq Mix (1 mL), 
internal control armored RNA (1uL, ~100 copies) and template (5 mL).  The internal control 
armored RNA was lysed by heating to 70°C for 4 min prior to addition to the mix.  The final 
concentration of each primer and MgSO4 was 0.4 mM and 3.5 mM, respectively. The RT-PCR 
thermal cycling protocol was 55°C for 30 min, 95°C for 2 min, then 35 cycles of 95°C for 15 s, 
60°C for 30 s, and 72°C for 15s, followed by 72°C for 2 min with a final 4°C hold.
2.9. Microsphere array hybridization
A wash-assay format was adopted to reduce variability of the response caused by non-specific 
hybridization of PCR products and fluorescent label. In a 96-well plate, RT-PCR product (1 mL) 
was added to a mixed suspension of probe-conjugated microspheres (22 mL) then placed in a 
thermal cycler and subjected to 95ºC for 2 min, 55ºC for 5 min, followed by a 4ºC hold. Tris-
NaCl buffer (100 mL, 0.1M Tris, 0.2 M NaCl, 0.05% v/v Triton X-100, pH 8.0, Teknova) was 
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added and the suspension was transferred to a 96-well vacuum filter plate (MABVN 1250
Multiscreen Filter Plate, Millipore).  The suspension was vacuum-aspirated, and washed twice 
with Tris-NaCl buffer (2 ×100 mL).  Stock streptavidin phycoerythrin (SAPE, 1 mg/mL, Caltag 
Laboratories) was diluted with Tris-NaCl to a working concentration of 3 mg/mL.  SAPE (60 mL, 
3 mg/mL) was added then incubated in the dark for 5 min.  The suspension was vacuum-
aspirated, washed once with Tris-NaCl (100 mL), re-suspended in Tris-NaCl (100 mL) then 
transferred to a 96-well round bottom plate for fluorescent detection.  Nucleic acid extraction, 
PCR reaction assembly and PCR amplification were conducted in separate rooms.  Likewise, 
hybridization and Bio-Plex detection were performed together in a separate room to minimize 
the likelihood of PCR contamination by amplicons. 
2.10. mRT-PCR detection  
Fluorescence detection of the processed microsphere suspension array was achieved using a 
Bio-Plex Workstation (Bio-Rad, CA) set to count a minimum of 100 events per microsphere 
class in a 50 mL Bio-Plex sample volume.  The Bio-Plex Workstation is a specialized dual-laser 
flow cytometer integrated with XY microplate platform configured to analyze Luminex xMAP®
microspheres in a 96-well plate format.  The reporter PMT voltage was calibrated on the low 
setting with background subtraction enabled.  The Bio-Plex workstation was validated and 
calibrated per the manufacturer’s instructions.  The resolution of the MFI was 0.5 units for all 
channels.
2.11. mRT-PCR assay controls  
The multiplex assay incorporates four control channels integral to each reaction that are used 
to verify assay integrity. The negative control (NC) is a microsphere conjugated to Thermotoga 
maratima-derived oligonucleotide sequence (MT-7) that serves as a non-specific binding control 
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in the multiplex PCR assay, and its response should remain consistently low (MFI≤80). The 
fluorescence control (FC), biotinylated MT-7, confirms that fluorescent labeling with SAPE 
occurred and should exhibit a high response (MFI >1000).  The instrument control (IC) 
comprises a Cy3-labeled MT-7 conjugate.  As Cy3 and SAPE have similar fluorescence 
excitation and emission wavelengths, the IC confirms proper function of the reporter optics 
within the Bio-Plex flow cytometer (MFI>500).  Armored RNA served as an end-to-end 
amplification control (AC) to reduce the probability of false negative and is utilized at low 
concentrations (100 copies/reaction) to generate a low-level response (MFI ≥20) which 
minimizes its competition with detection channels.  The armored RNA (XenoRNA-01, Ambion, 
Austin, TX) is a proprietary 1070 nucleotide RNA transcript consisting of unique nucleotide 
sequences that possess no significant homology to the current annotated sequences in commonly 
used sequence databases including NCBI, Affymetrix, and Rosetta.  Primers and probe-labeled 
microsphere for the AC are included in the multiplex primer mix and microsphere suspension, 
respectively.  
2.12. mRT-PCR assay integrity 
Minimum bead count quota and control channel responses were used to verify the integrity of 
the detection channel responses which minimizes the likelihood of false positives and false-
negative results caused by operator error, instrument malfunction, non-specific hybridization, or 
PCR inhibition. A flowchart summarizing the algorithm is shown in Figure 2. If a low bead 
count for any control channel occurred, then all results for that sample were considered invalid.  
The responses of all detection channels are checked against pre-established cut-offs then 
identified as mRT-PCR positive, negative or inconclusive.  For each sample, the MFI of each 
control bead class was checked against a cut-off value.  A given result was considered invalid 
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when the MFI value of the IC, NC or FC controls was out of range, or when both the response of 
the AC was <20 and no detection channels exceeded cut-off. Results were considered valid when 
the AC was <20 and any detection channel exceeded cut-off.  The AC response can be 
diminished by a strong positive response on a detection channel caused by competition in the 
RT-PCR reaction.  If the responses of all control channels are acceptable, the number of beads 
counted for control and detection channels are checked (≥40 beads per channel).  A low bead 
count on a given detection channel was considered an invalid result for the channel in question.  
Figure 2: Algorithm used to verify mRT-PCR assay integrity.
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2.13. Data analysis  
Raw data exported from the Bio-Plex instrument were imported into MATLAB (MathWorks) 
then analyzed using Microsoft Excel.  If at least one result from a duplicate sample analysis 
exceeded cut-off, the sample was assigned as mRT-PCR positive.  Receiver Operating 
Characteristic (ROC) plots (24) were generated using a custom MATLAB program.  Published 
guidelines (25) were followed for the calculations of diagnostic test accuracy and statistical 
methods to quantify uncertainty. 
2.14. Cut-off values 
The mRT-PCR responses for this assay are typically non-Gaussian and therefore non-
parametric methods were used to determine cut-offs.  Each channel in the multiplex has a distinct 
distribution of responses to true negative samples and therefore each is assigned its own cut-off 
value. For each detection channel of the mRT-PCR assay, the responses to true negative samples 
were ranked according to magnitude, then cut-off values were identified as the response (MFI 
value) which gave a false positive rate closest to 5% (without exceeding 5%), corresponding to a 
diagnostic specificity of at least 95% (3D MFI ≥ 6.5, 5´UTR MFI ≥ 5.5).  Cut-offs for all mRT-
PCR detection channels are shown in Table 2.  For rRT-PCR, the cut-off was Ct ≤32 for both 3D 
and 5´UTR assays (34).  
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Table 2: Cut-offs for each detection channel of the multiplex RT-PCR assay.
Detection 
channel
Cut-off 
(MFI)
BHV-1 7.5
BHV-2 5.5
PPOX-1 7.5
PPOX-2 316
PPOX-3 9.5
FMDV 3D 6.5
FMDV 5´UTR 5.5
BVD 6.5
BTV-1 6.5
BTV-2 6.5
SVD-1 7.5
SVD-2 8.5
SVD-3 10.5
VESV-1 6.5
VESV-2 18.5
VESV-3 18
VESV-4 22.5
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3. Results
3.1. Clinical sample validation.  
Receiver Operating Characteristic (ROC) plots were constructed to compare the diagnostic 
performance of the 3D and 5´UTR assays in rRT-PCR and mRT-PCR formats (Figure 3). 
Figure 3: Receiver Operating Characteristic (ROC) plots for the RNA polymerase (3D) 
and the 5´untranslated region (5´UTR) assays in singleplex real-time reverse transcriptase 
PCR (rRT-PCR) and multiplexed reverse transcriptase polymerase chain reaction (mRT-
PCR) formats.  True positive samples (n=213) representative of all FMDV serotypes and 
true negative samples (n=74) were analyzed.  The area under the curves are; 3D rRT-
PCR (0.985), 5´UTR rRT-PCR (0.942), 3D mRT-PCR (0.955) and 5´UTR mRT-PCR 
(0.773).
For the purpose of this evaluation, VI with Ag-ELISA served as the reference method and 
therefore assigned samples as true negative or true positive, with the caveat that rRT-PCR is 
known to detect FMDV in some samples considered negative by VI with Antigen-ELISA (35).  
Each plot shows the true positive fraction (TPF; sensitivity) versus the false positive fraction 
(FPF; 1-specificity) over the entire range of cut-off values.  The ROC plots indicate that the 3D 
and 5´UTR assays in mRT-PCR format lost some ability to distinguish between true negative 
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and true positive samples, as compared to rRT-PCR.  The associated areas under each ROC 
curve also indicate the level of test performance in the absence of a cut-off value.  Transfer to the 
multiplex format had the greatest effect upon the 5´UTR assay where the area under the curve 
was reduced to 0.773 in comparison to 0.942 for the rRT-PCR format.  In contrast, the effect 
upon the 3D assay was less apparent: 0.955 and 0.985 for the mRT-PCR and rRT-PCR formats 
respectively.  The ROC plots were generated using 3D and 5´UTR assay results independently.  
In practice, 3D and 5´UTR assay results would be used in combination, an intrinsic feature of the 
mRT-PCR format.  The trade-off between TPF and FPF shown by ROC plots can be used to 
inform cut-off selection.  The cut-off value for all detection channels was determined from the 
mRT-PCR response to true negative samples (n=74) using a specificity of 95%.  
Table 2 summarizes the performance metrics of the 3D and 5´UTR assays when used 
independently or in combination for both formats. Results are presented according to serotype 
then summarized for all serotypes.  In some cases, the rRT-PCR response for true positive 
samples (3D; n=5, 5´UTR; n=9) and true negative samples (3D; n=5, 5´UTR; n=2) yielded Ct 
values that were beyond the cut-off.  In practice, these samples would be considered weak rRT-
PCR positives and retested.
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Table 3: Performance metrics for the 3D and 5´UTR FMDV assays in rRT PCR and mRT-
PCR formats using independent or combined results.
rRT-PCR mRT-PCRPerformance metric
3D 5´UTR Combined 3D 5´UTR Combined
Sensitivity (%)  A
(Fraction)               
93.5
(43/46)
87.0
(40/46)
97.8
(45/46)
80.4
(37/46)
76.1
(35/46)
93.5
(43/46)
Asia 1 100
(10/10)
100
(10/10)
100
(10/10)
100.0
(10/10)
100
(10/10)
100
(10/10)
C 95.0
(19/20)
95.0
(19/20)
95.0
(19/20)
85.0
(17/20)
55.0
(11/20)
90.0
(18/20)
O 96.7
(87/90)
86.7
(78/90)
97.8
(88/90)
91.1
(82/90)
70.0
(63/90)
92.2
(83/90)
SAT 1 100.0
(18/18)
88.9
(16/18)
100
(18/18)
100
(18/18)
16.7
(3/18)
100
(18/18)
SAT 2 100.0
(21/21)
71.4
(15/21)
100
(21/21)
95.2
(20/21)
9.5
(2/21)
95.2
(20/21)
SAT 3 100.0
(8/8)
100
(8/8)
100
(8/8)
100
(8/8)
12.5
(1/8)
100
(8/8)
All 96.7
(206/213)
87.3
(186/213)
98.1
(209/213)
90.1
(192/213)
58.7
(125/213)
93.9
(200/213)
C.I. (95%) 93.4-98.4 82.2-91.1 95.3-99.3 85.4-93.5 52-65.1 89.8-96.4
Specificity (%) 94.6 95.9 93.2 93.2 94.6 91.9
C.I. (95%) 86.9-97.9 88.7-98.6 85.1-97.1 85.1-97.1 86.9-97.9 83.4-96.2
Sample Disease 
Prevalence (%) 74.2 74.2 74.2 74.2 74.2 74.2
PPV (%) 98.1 98.4 97.7 97.5 96.9 97.1
NPV(%) 90.9 72.4 94.5 76.7 44.3 84.0
Efficiency (%) 96.2 89.5 96.9 90.9 67.9 93.4
Sensitivity is the fraction of the 213 true positive epithelial tissue samples (subjected to 
both multiplex RT-PCR and rRT-PCR assays) that are assigned as FMDV-positive by the 
indicated assay.  C.I. Confidence Interval, PPV Positive Predictive Value, NPV Negative 
Predictive Value.
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Table 3 shows a three-way comparison of mRT-PCR and rRT-PCR against the reference 
method using the combined 3D and 5´UTR assay results.  
Table 4: 3-Way comparison table for the combined results of 3D and 5´UTR assays in 
rRT-PCR and mRT-PCR formats. 
Method Result True Diagnosis
Combined
rRT-PCR
Combined
mRT-PCR
Total Samples
Positive Negative
Positive Positive 202 200 2
Positive Negative 12 9 3
Negative Positive 4 0 4
Negative Negative 69 4 65
Total 287 213 74
The agreement between mRT-PCR and rRT-PCR for true positive samples was 95.8% 
(204/213).  Two samples classified as FMDV-negative by VI and Ag- ELISA tested positive by 
both formats (SYR 6/2002, LAO 16/2003).  Similarly, three samples (SYR 7/2002, TUR 
17/2002, BHU 5/2004) which were negative by VI and Ag-ELISA tested positive by rRT-PCR 
but were negative by mRT-PCR due to its higher LOD.  These findings are consistent with 
earlier studies (14, 35) where higher analytical sensitivity of rRT-PCR enabled detection of 
FMDV in samples designated negative by VI and Ag-ELISA.  Due to its higher LOD, the mRT-
PCR missed 9/209 positive samples detected by rRT-PCR.  Four mRT-PCR false positives had 
MFI responses that were close to the cut-off which was defined using a specificity of 95%.  Four 
mRT-PCR and rRT-PCR false negatives were samples of FMDV serotype A (NIG 12/74), C 
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(PHI 2/89) and O (O1 Manisa TUR 8/69, YEM 1/2001).  However, the rRT-PCR did generate Ct
responses for two of these samples including PHI 2/89 (3D; 38.94, 5´UTR; 38.51) and O1
Manisa (3D; 32.71).  As the Ct values were beyond the cut-off they would be considered weak
rRT-PCR positives and retested.  These false negatives which generated either weak or no 
responses in mRT-PCR and rRT-PCR formats were likely caused by mutations in the FMDV 
gene segments targeted by the 3D and 5´UTR assays. They could also be due to low amounts of 
virus present, particularly for O1 Manisa, which is a titrated sample used as a positive control in 
the diagnostic rRT-PCR that was deliberately set to be only weakly positive.
In addition to the 287 samples used to evaluate the mRT-PCR assay, eleven additional suspect 
FMDV field samples of undetermined serotype were analyzed. These samples were found to be 
negative by VI and Ag-ELISA but confirmed positive by combined 3D and 5´UTR rRT-PCR
during a previous study.  These samples were analyzed by the mRT-PCR assay, which detected 
11/11 of these samples, demonstrating that the multiplex also detects FMDV in clinical samples 
that were most likely rendered non-viable for VI between collection and laboratory receipt.
3.2. Limit of detection
The limit of detection (LOD) of the 3D and 5´UTR assays in mRT-PCR and rRT-PCR formats 
were compared using serially diluted clinical samples of serotype O or SAT 2 (Figure 4).  At the 
defined cut-off values, the mRT-PCR LOD was higher than rRT-PCR by approximately 5-625 
times for the 3D assay, and 25-125 times for 5´UTR, depending on serotype.  The higher LOD of 
the mRT-PCR therefore caused the loss of diagnostic performance evident in the ROC plots. 
Further assay optimization efforts are underway to improve the limits of detection of the 3D and 
5´UTR assays in the mRT-PCR format.   
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Figure 4: Comparison of the RNA polymerase (3D) and 5´untranslated region (5´UTR) 
assay responses in multiplex RT-PCR and singleplex rRT-PCR formats by consecutive 5-
fold serial dilutions of three different FMDV true positive epithelial suspension samples 
(undiluted to more dilute from right to left).  The multiplex RT-PCR detection was less 
sensitive than singleplex rRT-PCR (approximately 5-625 times and 25-125 times, 
respectively for 3D and 5´UTR signatures).  Cut-off values for rRT-PCR (Ct ≤ 32) and 
mRT-PCR (3D MFI ≥ 6.5, 5´UTR ≥ 5.5) are indicated by the vertical and horizontal 
dashed lines, respectively.  The 5´UTR signature did not respond to the SAT 2 (SAU 
4/2000) sample at any dilution in singleplex or multiplex formats and was omitted from 
the plot.  Error bars indicate ±1σ of the mean (n=2) response from the signature in mRT-
PCR format.  For rRT-PCR each sample was analyzed in singlet (n=1).
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3.3. Differential detection
Characterization of the diagnostic accuracy of the look-alike disease assays within the mRT-
PCR assay is ongoing and will be reported separately.  The mRT-PCR assay was positive with 
three SVDV field samples (ITL 4/77, HKN 1/80, HKN 5/91), two VESV isolates (serotypes -
B51 and -H54), San Miguel sea lion virus (serotypes SMSV-7, -9, -10, -11 and -13) and cetacean 
calicivirus (CCV, Tur-1, dolphin).  The mRT-PCR did not detect VESV -B1-34, other VESV 
serotypes including bovine (Bos-1 (Tillamook)), feline (A4), reptile (rattlesnake), and skunk, and 
VSV (serotype NJ 15/88 CP211634 and Indiana 1 subtype Ind 2 Maipu Argentina).  Feline 
calicivirus is in a distinct genomic group from the other VESV viruses tested and was not 
expected to be detected by this assay.  mRT-PCR identified look-alike disease viruses in four 
suspect FMD field samples that had previously been designated FMDV-negative by VI and rRT-
PCR (Figure 5). 
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Figure 5: Multiplex RT-PCR assay identification of FMDV look-alike disease viruses in 
suspect FMDV clinical sample submissions.  The mRT-PCR assay ruled out FMDV 
whilst simultaneously ruling in FMD look-alike disease viruses.  A and B show the multi-
loci detection of parapox viruses.  C shows BVDV detection in field samples from cattle 
(UKG 36/94, UKG 37/94) that were tested FMDV-negative by virus isolation and rRT-
PCR and the simultaneous detection of FMDV and BVDV (HUN 2/72).  mRT-PCR cut-
offs indicated by the vertical dashed lines were PPOX 1 (≥ 7.5), PPOX 3 (≥ 9.5) and 
BVDV (≥ 6.5). The horizontal dashed lines indicate the cut-off for FMDV 3D (≥ 6.5).
Two samples from cattle (IRN 4/2002, IRQ 58/2002) were mRT-PCR positive for 
parapoxvirus.  The parapox-3 assay generated the strongest response, however all three assays 
exceeded their respective cut-off values for both samples.  Two further cattle samples (UKG 
36/94, UKG 37/94) were mRT-PCR positive for BVDV that were also confirmed FMDV-
negative by all methods.  The mRT-PCR simultaneously detected the co-infection of FMDV and 
BVDV in a FMDV true positive sample (HUN 2/72).  The presence of BVDV, which causes a 
prevalent disease of cattle, did not mask the detection of FMDV.  
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Cross-talk between detection channels was minimal, even at the relatively high concentrations 
of FMDV RNA in many of the field samples tested.  A matrix of correlation coefficients for all 
channel pairings was calculated using the results of all FMDV true positive samples (n=213).  
The correlation coefficients of the 3D and 5´UTR channels with other channels did not exceed 
0.209 and 0.114, respectively.  
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4. Discussion
The mRT-PCR assay was able to detect FMDV at clinically relevant concentrations.  The 
apparent concentration of FMDV in the clinical samples was relatively high as might be 
expected with vesicular epithelial tissue which, when infected, is rich in virus.  The performance 
of mRT-PCR and singleplex rRT-PCRs was compared using VI and Ag-ELISA to define FMDV 
true positives and true negatives.  Although VI and Ag-ELISA are established methods for the 
detection of FMDV, previous studies (14, 35) have demonstrated that rRT-PCR has higher 
diagnostic sensitivity and can detect virus in additional samples, which for the purposes of this 
study would be classified as “true” negatives.  For the majority of true positive field samples, the 
3D mRT-PCR response was saturated and grouped far from the cut-off.  The 5´UTR mRT-PCR 
signal was generally lower and clustered on either side of the cut-off.  The higher LOD of both 
assays in the mRT-PCR format may be caused by low-level non-specific interactions between 
primer sets that could reduce amplification efficiency.  The primers used in the 5´UTR assay 
were not originally designed with multiplexing in mind. In order to recognize a wide range of 
FMDV isolates, the 5’UTR primers have a high degree of degeneracy (32-fold and 8-fold for the 
forward and reverse primers respectively) that could increase the likelihood of non-specific 
interactions with other primer sets in the multiplexed reaction mixture.  Whilst primer probe sets 
incorporating degenerate nucleotides can offer broader coverage of highly-variable gene 
segments, further work is required to refine their design for multiplexed assays.  Asymmetric 
PCR and multivariate optimization may lead to further improvements in the LODs of the 3D and 
5´UTR mRT-PCR assays.  
The 3D and 5´UTR assay responses had serotypic bias, a finding which agrees with earlier 
observations (4, 14).  In mRT-PCR format, the 3D assay was less sensitive for A and C serotypes 
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whereas the 5´UTR was less effective against SAT serotypes.  For all serotypes collectively, the 
3D assay was more sensitive than the 5´UTR within each format (rRT-PCR 3D 96.7% vs. 
5´UTR 87.3%, mRT-PCR 3D 90.1% vs. 5´UTR 58.7%).  In an earlier evaluation of the rRT-
PCR assays (14), the diagnostic sensitivity of the 3D (97.7 %) was found to be slightly higher 
than the 5´UTR assay (95.4%).  The diagnostic sensitivity increased when the results of the 3D 
and 5´UTR assays were used in combination.  This is due to the “or” nature of the combination, 
whereby a single mRT-PCR positive result on the 3D or 5´UTR channel generates a combined 
mRT-PCR positive result.  The diagnostic sensitivity of the combined mRT-PCR assay was 
93.9%, compared to 98.1% for combined rRT-PCR.  The loss of diagnostic sensitivity from rRT-
PCR to mRT-PCR, due to higher limits of detection, was partially offset by the inherent ability 
of the multiplex assay to screen multiple loci simultaneously.  Combined rRT-PCR only 
increased the diagnostic sensitivity by 1.4% compared to using the 3D rRT-PCR assay in 
isolation which could factor into the cost-benefit of conducting parallel assays.  As the mRT-
PCR is a screening assay that would most likely be used in conjunction with confirmatory tests, 
potential users may be more tolerant of lower specificity in order to achieve higher sensitivity.  
The negative predictive value was also higher for combined assays, because of the “or” nature of 
the combined result as false negatives only occurred when both the 3D and 5´UTR results 
agreed.  
The differential detection of FMDV from look-alike disease viruses, which included ssRNA 
and dsDNA targets, was demonstrated by testing representative isolates of SVDV, VESV and 
VSV.  For a diagnostic laboratory, this could produce time and cost savings, when compared to 
testing for each disease using singleplex rRT-PCR assays.  For veterinarians, the mRT-PCR 
assay could increase confidence in a sample identified as FMDV-negative by simultaneously 
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screening for the presence of look-alike diseases.  For networks of veterinary diagnostic 
laboratories, an mRT-PCR assay could facilitate embedded foreign animal disease surveillance 
whilst conducting routine testing of endemic animal disease viruses. An inter-laboratory 
evaluation of this multiplex assay was recently conducted in fourteen US National Animal 
Health Laboratory Network laboratories; the results suggested the mRT-PCR technology could 
be operated successfully in this setting.  The diagnostic performance evaluation for the look-alike 
disease assays in the mRT-PCR format is underway and will be reported separately.  
The mRT-PCR format is compatible with procedures and instrumentation used for rRT-PCR.  
The use of a single method to prepare clinical samples for mRT-PCR and rRT-PCR analysis was 
demonstrated in this study.  The mRT-PCR requires the post-processing of RT-PCR product to 
the microsphere array which takes ~50 min per 96-well plate using manually operated multi-
channel pipettes. The 96-well plate format provides convenient interchangeability between 
manual and automated platforms. With this reagent set, the Bio-Plex flow cytometer analyzed 
each well in ~40 s, or ~1 h per 96-well plate.   Although the diagnostic sensitivity of the mRT-
PCR for FMDV detection is slightly lower than singleplex rRT-PCR, it provides significantly 
more diagnostic information.  With 17 detection channels for seven different viruses, the current 
prototype panel generates 1632 individual assay results per 96-well plate. The microsphere 
suspension array is a versatile platform compatible with many different types of diagnostic tests, 
including immunological and serological assays which could increase its utility within a 
veterinary diagnostic laboratory, not only for outbreak response and recovery but also for routine 
testing for endemic diseases.  The inherent flexibility of the Luminex array also enables the 
composition of a given multiplex assay to be altered by simply adding or removing detection 
channels.  Refinements to the first version of the mRT-PCR assay described herein are currently 
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underway, including the development of two species-specific panels for more comprehensive 
coverage.  These new panels incorporate additional assays for other FMDV look-alike diseases.  
The bovine-specific panel incorporates assays for FMD, Malignant Catarrhal Fever (MCF), 
Rinderpest, Bluetongue, BHV-1, BVD, Parapox and VS.  The porcine-specific panel includes 
assays for FMD, SVD, VES, VS and Porcine Reproductive and Respiratory Syndrome (PRRS).
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7. Appendix
7.1. Area under the curve for ROC plots
Table 5: Area under the curve for ROC plots for the independent results of the 5'UTR and 
3D assays in rRT-PCR and mRT-PCR formats. 
rRT-PCR mRT-PCRSerotype
5'UTR 3D 5'UTR 3D
A 0.933 0.974 0.847 0.909
Asia 1.000 1.000 0.960 0.981
C 0.991 0.986 0.863 0.941
O 0.941 0.983 0.815 0.958
SAT 1 0.920 0.997 0.548 1.000
SAT 2 0.901 0.997 0.553 0.984
SAT 3 0.971 0.997 0.536 1.000
All 0.942 0.985 0.773 0.955
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7.2. Receiver Operating Characteristic (ROC) Plots
Figure 6: ROC plots for independent 3D and 5'UTR assays in rRT-PCR and mRT-PCR 
formats according to individual FMDV serotype and for all serotypes. VI with Ag-ELISA 
was the reference method used to assign samples as true negative of true positive.
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7.3. Response of 3D mRT-PCR assay vs 3D rRT-PCR assay according to FMDV serotype
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Figure 7. Comparison of the 3D assay response in mRT-PCR and singleplex rRT-PCR 
formats, where response is reported as median fluorescence intensity (MFI) and cycle 
threshold (Ct), respectively.  Results for 287 samples plotted according to FMDV 
serotype as determined by antigen-ELISA of the original suspension or cell culture 
supernatant.  Cut-off values for rRT-PCR (Ct ≤ 32) and mRT-PCR (3D MFI ≥ 6.5) are 
indicated by the vertical and horizontal dashed lines, respectively.  Error bars indicate 
±1σ of the mean (n=2) response from the signature in mRT-PCR format.  For rRT-PCR 
each sample was analyzed in singlet (n=1).
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7.4. Response of 5'UTR mRT-PCR assay vs 5'UTR rRT-PCR assay according to FMDV 
serotype
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Figure 8. Comparison of the 5´UTR assay response in mRT-PCR and singleplex rRT-
PCR formats, where response is reported as median fluorescence intensity (MFI) and 
cycle threshold (Ct), respectively.  Results for 287 samples plotted according to FMDV 
serotype as determined by antigen-ELISA of the original suspension or cell culture 
supernatant.  Cut-off values for rRT-PCR (Ct ≤ 32) and mRT-PCR (5´UTR ≥ 5.5) are 
indicated by the vertical and horizontal dashed lines, respectively.  Error bars indicate 
±1σ of the mean (n=2) response from the signature in mRT-PCR format.  For rRT-PCR 
each sample was analyzed in singlet (n=1).
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7.5. Calculation of performance estimates
The performance of the mRT-PCR was compared to singleplex rRT-PCR, using VI and Ag-
ELISA to define FMDV true positives and true negatives.  Although VI and Ag-ELISA are 
established methods for the detection of FMDV, previous studies have demonstrated that rRT-
PCR has higher diagnostic sensitivity and can detect virus in additional samples, which for the 
purposes of this study would be classified as “true” negatives.  
Performance estimates are calculated from test results run in parallel on all samples, as illustrated 
in Table 6.
Table 6: Theoretical 2×2 table. 
True Diagnosis
Positive Negative Total
Positive A B A + B
Negative C D C + D
Total A + C B + D N
Sensitivity = 100%[A/(A+C)]
95% Confidence Interval (C.I.) for sensitivity = [100%(Q1-Q2)/Q3, 100%(Q1+Q2)/Q3]
Where Q1 = 2A+3.84
Q2 = 1.96[3.84+4AC/(A+C)]^0.5
Q3 = 2(A+C)+7.68
Estimated Specificity = 100%[D/(B+D)]
95% Confidence Interval (C.I.) for specificity = [100%(Q1-Q2)/Q3, 100%(Q1+Q2)/Q3]
Where Q1 = 2D+3.84
Q2 = 1.96[3.84+4BD/(B+D)]^0.5
Q3 = 2(B+D)+7.68
Disease prevalence = 100%[(A+C)/N]
Positive Predictive Value = 100%[A/(A+B)]
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Negative Predictive Value = 100%[D/(C+D)]
Efficiency = 100%[(A+D)/N]
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7.6. Diagnostic sensitivity and specificity estimates 
7.6.1. 3D rRT-PCR 2×2 Table
Table 7: 3D rRT-PCR 2×2 table using VI with Ag-ELISA as the reference method. 
True Diagnosis
Positive Negative Total
Positive 206 4 210
Negative 7 70 77
Total 213 74 287
7.6.2. 5´UTR rRT-PCR 2×2 Table
Table 8: 5´UTR rRT-PCR 2×2 table using VI with Ag-ELISA as the reference method. 
True Diagnosis
Positive Negative Total
Positive 186 3 189
Negative 27 71 98
Total 213 74 287
7.6.3. Combined rRT-PCR 2×2 Table
Table 9: Combined rRT-PCR 2×2 table using VI with Ag-ELISA as the reference 
method. 
True Diagnosis
Positive Negative Total
Positive 209 5 214
Negative 4 69 73
Total 213 74 287
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7.6.4. 3D mRT-PCR 2×2 Table
Table 10: 3D mRT-PCR 2×2 table using VI with Ag-ELISA as the reference method. 
True Diagnosis
Positive Negative Total
Positive 192 5 197
Negative 21 69 90
Total 213 74 287
7.6.5. 5´UTR mRT-PCR 2×2 Table
Table 11: 5´UTR mRT-PCR 2×2 table using VI with Ag-ELISA as the reference method. 
True Diagnosis
Positive Negative Total
Positive 125 4 129
Negative 88 70 158
Total 213 74 287
7.6.6. Combined mRT-PCR 2×2 Table
Table 12: Combined mRT-PCR 2×2 table using VI with Ag-ELISA as the reference 
method. 
True Diagnosis
Positive Negative Total
Positive 200 6 206
Negative 13 68 81
Total 213 74 287
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7.7. Detection channel cross-talk
Table 13: Correlation coefficients between the mRT-PCR FMDV 3D or 5´UTR detection 
channels with the other fifteen detection channels. 
Correlation Coefficient
All samples FMDV + samples
Assay
FMDV 3D FMDV 5´UTR FMDV 3D FMDV 5´UTR
BHV-1 -0.107 -0.003 -0.195 -0.017
BHV-2 0.167 0.055 0.123 0.037
PPOX-1 -0.075 -0.021 0.029 0.009
PPOX-2 -0.078 -0.092 -0.168 -0.156
PPOX-3 -0.076 -0.019 0.015 0.114
BVDV -0.087 -0.027 -0.083 -0.023
BTV-1 0.067 0.024 0.074 0.022
BTV-2 0.009 0.057 0.046 0.080
SVD-1 -0.054 -0.034 -0.102 -0.048
SVD-2 -0.027 -0.140 0.011 -0.141
SVD-3 -0.001 -0.108 0.067 -0.102
VESV-1 -0.069 -0.053 -0.089 -0.059
VESV-2 0.085 -0.069 0.209 -0.053
VESV-3 0.005 -0.075 0.070 -0.077
VESV-4 0.047 -0.141 0.145 -0.135
“All samples” contains 550 measurements from 213 FMD-positive samples and 74 FMD-
negative samples. “FMD+ samples” contains 417 measurements from 213 FMD-positive 
samples. In “all samples”, the correlation coefficients between FMDV 3D and FMDV 
5´UTR channels with all other detection channels did not exceed 0.167 and 0.057, 
respectively. In “FMD+ samples”, the correlation coefficients between FMDV 3D and 
FMDV 5´UTR channels with all other detection channels did not exceed 0.209 and 0.114, 
respectively.
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7.8. Raw data for 287 samples used for the diagnostic evaluation of the mRT-PCR assay.
Table 14: Raw data for 287 samples used for the diagnostic evaluation of the mRT-PCR 
assay.  Table key: + = positive, - = negative. mRT-PCR results key: ++ = positive for 
both duplicate measurements, -- = negative for both duplicate measurements, +/- = 
positive in one duplicate and negative in other duplicate, + = positive in one duplicate 
and the other duplicate not performed, - = negative in one duplicate and the other 
duplicate not performed
Isolate Serotype 3D
rRT-PCR
5'UTR
rRT-PCR
Combined
rRT-PCR
3D
mRT-PCR
5'UTR
mRT-PCR
Combined
mRT-PCR
ARG 1/2001 FMD A + + + + + + + +
BHU 35/2003 FMD A + - + + + +
BHU 35/2003 FMD A + + + - - + - +
BHU 41/2002 FMD A + + + + - + - +
BHU 6/2003 FMD A + + + + + +
BHU 6/2003 FMD A + + + + + + + +
ERI 3/98 FMD A + + + + + - - +
IRN 10/2003 FMD A + + + + + + + +
IRN 10/2005 FMD A + + + + + + + +
IRN 14/2005 FMD A + + + + + + - +
IRN 16/2005 FMD A + + + + + + + +
IRN 17/2005 FMD A + + + + + - - +
IRN 21/2000 FMD A + + + + + - - +
IRN 26/2003 FMD A + + + + + + + +
IRN 4/2000 FMD A + + + + + + + +
IRN 41/2003 FMD A + + + + + + + +
IRN 5/2003 FMD A + + + + + - - +
IRN 6/2002 FMD A + - + + + +
IRN 7/2000 FMD A + - + + + - - +
IRN 7/2004 FMD A + + + + + + - +
IRQ 59/2002 FMD A + + + + + + + +
MAI 4/2004 FMD A + - + - - - - -
MAY 4/2003 FMD A + + + + + + + +
NIG 12/1974 FMD A - - - - - - - -
PAK 20/2006 FMD A + + + + + + + +
PAK 21/2006 FMD A + + + + + + + +
PAK 22/2006 FMD A + + + + + - - +
PAK 23/2006 FMD A + + + + + + + +
PAK 25/2006 FMD A + + + + + + + +
PAK 28/2002 FMD A + + + + + + - +
PAK 77/2003 FMD A + + + + + + - +
SYR 5/2002 FMD A + + + + + - - +
SYR 5/2002 FMD A + + + + + + + +
SYR 9/2002 FMD A - + + - - + + +
TAI 3/2001 FMD A + + + + - + + +
TAI 4/2003 FMD A + + + + + + + +
TAI 4/2003 FMD A + + + + + + + +
TOG 9/2005 FMD A + - + + + - - +
TUR 1/2000 FMD A + + + + + + + +
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Isolate Serotype 3D
rRT-PCR
5'UTR
rRT-PCR
Combined
rRT-PCR
3D
mRT-PCR
5'UTR
mRT-PCR
Combined
mRT-PCR
TUR 1/2000 FMD A + + + + + + + +
TUR 1/2002 FMD A + + + + - + - +
TUR 14/2002 FMD A + + + - - + + +
TUR 15/2002 FMD A + + + - - + + +
TUR 16/2002 FMD A + + + - - - - -
TUR 4/2000 FMD A - + + - - + + +
TUR 4/2003 FMD A + + + - - + - +
AFG 3/2001 FMD Asia 1 + + + + + + + +
BHU 27/2002 FMD Asia 1 + + + + + + + +
GRE 2/2000 FMD Asia 1 + + + + + + + +
HKN 8/2005 FMD Asia 1 + + + + + + + +
IND 5/89 FMD Asia 1 + + + + + + + +
IRN 30/2004 FMD Asia 1 + + + + + + + +
PAK 1/2004 FMD Asia 1 + + + + + + + +
PAK 48/2003 FMD Asia 1 + + + + - + - +
TAI 1/98 FMD Asia 1 + + + + + + + +
TUR 3/2000 FMD Asia 1 + + + + + + + +
ANG 2/73 FMD C + + + + + + + +
AUR 4/73 FMD C + + + + + - - +
BEL 1/69 FMD C + + + + + + + +
BEL 1/72 FMD C + + + + + - - +
C ARG/84 FMD C + + + + + +
FRA 3/74 FMD C + + + + + - - +
HUN 2/72 FMD C + + + + + - - +
IND 16/81 FMD C + + + + + + + +
ISO 3 bovine EPI FMD C + + + + + - - +
ISO 5 NV 19 FMD C + + + + + - - +
ITL 4/89 FMD C + + + + + - - +
KUW 9/82 FMD C + + + + + + + +
PHI 2/89 FMD C - - - - - - - -
PHI 3/94 FMD C + + + - - + + +
PHI 3/94 FMD C + + + - - - - -
SAU 14/84 FMD C + + + + + + + +
SRL 4/78 FMD C + + + + + + + +
UKG 70/74 FMD C + + + + + + - +
UKG 70/74 FMD C + + + + + + - +
USS 4/74 FMD C + + + + + + + +
BHU 22/2003 FMD O + - + + + - - +
BHU 48/2003 FMD O + + + + + + + +
BHU 7/2002 FMD O + + + + - + - +
BUN 6/2003 FMD O + + + + + - - +
CAM 13/99 FMD O + + + + + + + +
CAR 86/2005 FMD O + - + + + - - +
HKN 11/2004 FMD O + + + + + - - +
HKN 12/2005 FMD O + + + + + - - +
HKN 19/2001 FMD O + - + - - - - -
HKN 3/2003 FMD O + + + + - - - +
HKN 3/2004 FMD O + + + + + - - +
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Isolate Serotype 3D
rRT-PCR
5'UTR
rRT-PCR
Combined
rRT-PCR
3D
mRT-PCR
5'UTR
mRT-PCR
Combined
mRT-PCR
IRN 2/2003 FMD O + - + + + - - +
IRN 27/2003 FMD O + + + + + + + +
IRN 8/2001 FMD O + + + - - - - -
ISA 1/74 FMD O + + + + + + + +
ISA 9/74 FMD O + + + + + + + +
JOR 1/99 FMD O + + + + - + - +
KEN 5/2002 FMD O + + + + + - - +
KEN 5/2002 FMD O + + + + + + + +
KEN 6/2002 FMD O + + + + + - - +
LAO 1/2003 FMD O + + + + + + + +
LAO 17/2003 FMD O + + + + + + + +
LAO 2/2003 FMD O + + + + + + - +
LAO 21/2003 FMD O + + + + + +
LAO 26/2003 FMD O + + + + + + + +
LAO 29/2003 FMD O - + + - - - - -
LAO 31/2003 FMD O + + + + + + - +
LAO 34/2003 FMD O + + + + + + + +
LAO 7/2003 FMD O + + + + + + + +
LAO 8/98 FMD O + + + + + + - +
LEB 5/99 FMD O + - + + + + + +
MAI 2/2005 FMD O + + + + + + - +
MAU 15/2001 FMD O + - + + + + + +
MAU 19/2000 FMD O + - + + - + - +
MAY 1/2001 FMD O + + + + + + + +
MAY 1/2002 FMD O + + + + + + + +
MAY 2/2004 FMD O + + + + + + + +
MAY 5/2002 FMD O + + + + + +
MAY 6/2003 FMD O + + + + + + + +
MYA 1/2001 FMD O + + + + + + + +
MYA 4/2002 FMD O + + + + + + + +
NEP 12/2000 FMD O + + + + + + + +
NEP 13/2000 FMD O + + + + + + + +
NEP 4/2003 FMD O + + + + + - - +
NEP 6/2003 FMD O + + + + + + + +
NGR 11/2001 FMD O + + + + + + + +
O1 BFS 1860 Pig 
SE24 FMD O + + + + + + + +
O1 Manisa FMD O + - + - - + - +
O1 Manisa +ve FMD O + + + - - -
O1 Manisa +ve FMD O - - - - - - - -
O1 Manisa 3/5/2006 FMD O + + + - - -
O1 Manisa 
30/10/2006 FMD O + + + + + - - +
OMN 2/2001 FMD O + + + + + + + +
PAK 1/2003 FMD O + + + + + - - +
PAK 28/2006 FMD O + + + + + - - +
PAK 29/2006 FMD O + + + + + - - +
PAK 33/2006 FMD O + + + + + - - +
PAK 34/2006 FMD O + + + + + - - +
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Isolate Serotype 3D
rRT-PCR
5'UTR
rRT-PCR
Combined
rRT-PCR
3D
mRT-PCR
5'UTR
mRT-PCR
Combined
mRT-PCR
PAK 35/2006 FMD O + + + + + + - +
PAK 36/2006 FMD O + + + + + - - +
PAK 37/2006 FMD O + + + + + + - +
PHI 1/2005 FMD O + + + + + + + +
PHI 2/2005 FMD O + + + + + + + +
PHI 20/2003 FMD O + + + + + + + +
PHI 3/2005 FMD O + + + + + + + +
PHI 3/2005 FMD O + + + + + + + +
PHI 8/2001 FMD O + + + + + + + +
SAU 1/2002 FMD O + + + + + + + +
SRL 1/2000 FMD O + + + + + + + +
SYR 1/2002 FMD O + + + + + - - +
TAN 1/99 FMD O + + + + + + - +
TAW 84/94 FMD O + + + + + + + +
TAW 9/1997 FMD O + + + + + +
TOG 1/2004 FMD O + + + + + + - +
TUR 1/2003 FMD O + + + + + + +
TUR 3/2003 FMD O + + + + + + + +
TUR 5/2002 FMD O + + + + + + + +
UAE 2/2003 FMD O + + + + + + - +
UGA 4/2004 FMD O + - + + + - - +
UKG 13,305/2001 FMD O + + + + + + + +
UKG 14004/2001 FMD O + - + + + + - +
UKG 312/2001 FMD O + + + + + + + +
UKG 9804/2001 FMD O + + + + + + + +
URU 1/2000 FMD O + + + + - + + +
URU 1/2000 FMD O + + + + + + + +
VIT 13/2002 FMD O + + + + + + + +
VIT 19/99 FMD O + + + + + + + +
VIT 2/2002 FMD O + + + + + + + +
VIT 6/2002 FMD O + + + + + + + +
YEM 1/2001 FMD O - - - - - - - -
BOT 2/68 FMD SAT 1 + + + + + - - +
BOT 2/68 FMD SAT 1 + + + + + + + +
GHA 3/69 FMD SAT 1 + - + + + - - +
GHA 3/69 FMD SAT 1 + - + + + - - +
KEN 1/2005 FMD SAT 1 + + + + + + + +
KEN 1/2005 FMD SAT 1 + + + + + - - +
MOZ 11/78 FMD SAT 1 + + + + + - - +
RHO 1/80 FMD SAT 1 + + + + + - - +
RHO 5/66 FMD SAT 1 + + + + + + + +
RV 11/37 15/9/37 FMD SAT 1 + + + + + - - +
SAR 17/80 FMD SAT 1 + + + + + - - +
SAR 6/74 FMD SAT 1 + + + + + - - +
SWA 1/80 FMD SAT 1 + + + + + - - +
TAN 28/99 FMD SAT 1 + + + + + - - +
TAN 36/99 FMD SAT 1 + + + + + - - +
UGA 3/99 FMD SAT 1 + + + + + - - +
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Isolate Serotype 3D
rRT-PCR
5'UTR
rRT-PCR
Combined
rRT-PCR
3D
mRT-PCR
5'UTR
mRT-PCR
Combined
mRT-PCR
ZAM 28/2004 FMD SAT 1 + + + + + - - +
ZIM 3/85 FMD SAT 1 + + + + + - - +
BOT 1/2005 FMD SAT 2 + + + + + - - +
BOT 13/2002 FMD SAT 2 + + + + + - - +
BOT 13/2002 FMD SAT 2 + + + + + - - +
CAR 117/2005 FMD SAT 2 + - + + + - - +
CAR 5/2000 FMD SAT 2 + - + + + - - +
ERI 4/98 FMD SAT 2 + + + + + - - +
IVC 8/75 FMD SAT 2 + + + + + - - +
KEN 2/2002 FMD SAT 2 + + + + + - - +
KEN 7/2004 FMD SAT 2 + + + + + + + +
KEN 7/2004 FMD SAT 2 + + + + + - - +
LIB 1/2003 FMD SAT 2 + + + + + - - +
MAI 7/91 FMD SAT 2 + + + + + - - +
MAL 4/75 FMD SAT 2 + + + + + - - +
MOZ 20/78 FMD SAT 2 + + + + + - - +
RHO 3/80 FMD SAT 2 + + + + + + - +
SAU 13/2000 FMD SAT 2 + - + + + - - +
SAU 4/2000 FMD SAT 2 + - + + + - - +
SAU 4/20000 FMD SAT 2 + - + + + - - +
UGA 20/98 FMD SAT 2 + + + + + - - +
ZIM 11/91 FMD SAT 2 + - + - - - - -
ZIM 2/97 FMD SAT 2 + + + + + - - +
BEC 2/65 FMD SAT 3 + + + + + + + +
MAL 3/76 FMD SAT 3 + + + + + - - +
RHO 1/74 FMD SAT 3 + + + + + - - +
RHO 2/74 FMD SAT 3 + + + + + - - +
SAR 4/80 FMD SAT 3 + + + + + - - +
ZIM 1/84 FMD SAT 3 + + + + + - - +
ZIM 1/84 FMD SAT 3 + + + + + - - +
ZIM 6/91 FMD SAT 3 + + + + + - - +
BEN 1/2005 Negative - - - - - - - -
BEN 10/2005 Negative - - - - - - - -
BEN 11/2005 Negative - - - - - - - -
BEN 12/2005 Negative - - - - - - - -
BEN 13/2005 Negative - - - - - - - -
BEN 14/2005 Negative - - - - - - - -
BEN 15/2005 Negative - - - - - - - -
BEN 16/2005 Negative - - - - - - - -
BEN 2/2005 Negative - - - - - - - -
BEN 32005 Negative - - - - - - - -
BEN 4/2005 Negative - - - - - - - -
BEN 5/2005 Negative - - - - - - - -
BEN 6/2005 Negative - - - - - - - -
BEN 7/2005 Negative - - - - - - - -
BEN 8/2005 Negative - - - - - - - -
BEN 9/2005 Negative - - - - - - - -
IRL 5/2006 Negative - - - - - - - -
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IRL 6/2006 Negative - - - - - - - -
Neg Bov epi Negative - - - - - -
Neg Bov epi Negative - - - - - - - -
Neg Bov epi Negative - - - - - - - -
Neg Bov epi Negative - - - - - - - -
Neg Bov epi Negative - - - + - + - -
Neg Bov epi Negative - - - + + +
Neg Bov epi Negative - - - + - - - +
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
Neg Bov Epi 1/7/2006 Negative - - - - - - - -
NEG BOVINE EPI Negative - - - - - - - -
NEG BOVINE EPI Negative - - - - - - - -
Negative bovine Negative - - - - - - - -
Negative bovine Negative - - - - - - - -
Negative bovine Negative - - - - - - - -
Negative porcine Negative - - - - - + - +
Negative porcine Negative - - - - - - - -
BHU 1/2003 NVD - - - - - - - -
BHU 47/2002 NVD - - - - - - - -
BHU 5/2004 NVD + - + - - - - -
IRN 15/2005 NVD - - - - - - - -
IRN 4/2002 NVD - - - - - - - -
IRN 6/2005 NVD - - - - - - - -
IRQ 39/2002 NVD - - - - - -
IRQ 44/2002 NVD - - - - - - - -
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IRQ 58/2002 NVD - - - - - - - -
LAO 16/2003 NVD + + + + + + + +
SYR 6/2002 NVD + + + + + - - +
SYR 7/2002 NVD - + + - - - - -
TUR 17/2002 NVD + - + - - - - -
UKG 36/94 NVD - - - - - - - -
UKG 37/94 NVD - - - - - - - -
UKG 39/2002 NVD - - - - - - - -
UKG 40/2002 NVD - - - - - - - -
